Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer

Publication ,  Conference
Carey, LA; Rugo, HS; Marcom, PK; Irvin, W; Ferraro, M; Burrows, E; He, X; Perou, CM; Winer, EP
Published in: Journal of Clinical Oncology
May 20, 2008

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

1009 / 1009

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., … Winer, E. P. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. In Journal of Clinical Oncology (Vol. 26, pp. 1009–1009). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2008.26.15_suppl.1009
Carey, L. A., H. S. Rugo, P. K. Marcom, W. Irvin, M. Ferraro, E. Burrows, X. He, C. M. Perou, and E. P. Winer. “TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.” In Journal of Clinical Oncology, 26:1009–1009. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.1009.
Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 1009–1009.
Carey, L. A., et al. “TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2008, pp. 1009–1009. Crossref, doi:10.1200/jco.2008.26.15_suppl.1009.
Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, He X, Perou CM, Winer EP. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 1009–1009.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

1009 / 1009

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences